Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-6mft8 Total loading time: 0.37 Render date: 2021-10-21T10:49:55.781Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

Chapter 22 - Hyperhidrosis

Published online by Cambridge University Press:  05 February 2014

Henning Hamm
Affiliation:
Department of Dermatology, University of Würzburg, Würzburg, Germany
Markus K. Naumann
Affiliation:
Department of Neurology, Augsburg Hospital, Augsburg, Germany
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Hyperhidrosis may generally be defined as excessive sweating or sweating beyond physiological needs. It may be divided into generalized, regional and localized/focal types and, according to whether the cause is known or not, into primary/idiopathic and secondary forms. Secondary hyperhidrosis can be induced by a number of infectious, endocrine, metabolic, cardiovascular, neurological, psychiatric and malignant conditions; it can also be caused by certain drugs and poisoning. The prevalence of hyperhidrosis in the US population has been calculated at 2.8% (Strutton et al., 2004). Of those, primary axillary hyperhidrosis appears to be the most frequent type, severely affecting 0.5%.

Box 22.1 gives the diagnosis of primary focal hyperhidrosis set out by a multispecialty working group (Hornberger et al., 2004). It usually starts in childhood or adolescence and mainly involves the armpits, palms, soles and craniofacial region, either alone or in various combinations. There are well-known, particularly emotional, triggers of sweating episodes, but the exact pathogenesis of the sympathetic overstimulation of eccrine sweat glands is still poorly understood apart from a clear genetic background.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anders, D, Moosbauer, S, Naumann, MK, Hamm, H (2008). Craniofacial hyperhidrosis successfully treated with botulinum toxin type A. Eur J Dermatol, 18, 87–8.Google ScholarPubMed
Baumann, L, Slezinger, A, Halem, M et al. (2005). Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg, 31, 263–70.CrossRefGoogle ScholarPubMed
Campanati, A, Bernardini, ML, Gesuita, R, Offidani, A (2007). Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol, 17, 52–4.Google ScholarPubMed
Campanati, A, Sandroni, L, Gesuita, R et al. (2011). Treatment of focal idiopathic hyperhidrosis with botulinum toxin type A: clinical predictive factors of relapse-free survival. J Eur Acad Dermatol Venereol, 25, 917–21.CrossRefGoogle ScholarPubMed
Charrow, A, DiFazio, M, Foster, L, Pasquina, PF, Tsao, JW (2008). Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series. Arch Phys Med Rehabil, 89, 1407–9.CrossRefGoogle ScholarPubMed
Davarian, S, Kalantari, KK, Rezasoltani, A, Rahimi, A (2008). Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol, 49, 75–9.CrossRefGoogle Scholar
Doft, MA, Hardy, KL, Ascherman, JA (2012). Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J, 32, 238–44.CrossRefGoogle ScholarPubMed
Dressler, D (2010). Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm, 117, 317–19.CrossRefGoogle ScholarPubMed
Dressler, D, Adib Saberi, F, Benecke, R (2002). Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol, 249, 1729–32.CrossRefGoogle ScholarPubMed
Glaser, DA, Coleman, WP, Fan, LK et al. (2012). A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg, 38, 185–91.CrossRefGoogle ScholarPubMed
Hamm, H, Naumann, MK, Kowalski, JW et al. (2006). Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology, 212, 343–53.CrossRefGoogle ScholarPubMed
Heckmann, M, Ceballos-Baumann, AO, Plewig, G (2001). Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med, 344, 488–93.CrossRefGoogle Scholar
Hoorens, I, Ongenae, K (2012). Primary focal hyperhidrosis: current treatment options and a step-by-step approach. J Eur Acad Dermatol, Venereol 26, 1–8.CrossRefGoogle Scholar
Hornberger, J, Grimes, K, Naumann, M et al. (2004). Multi-Specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol, 51, 274–86.CrossRefGoogle Scholar
Kavanagh, GM, Shams, K (2006). Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. J Am Acad Dermatol, 55(Suppl):S115–17.CrossRefGoogle ScholarPubMed
Kim, WO, Kil, HK, Yoon, KB, Noh, KU (2009). Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg, 35(5):833–8.CrossRefGoogle ScholarPubMed
Kinkelin, I, Hund, M, Naumann, M, Hamm, H (2000). Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol, 143, 824–7.CrossRefGoogle ScholarPubMed
Lowe, NJ, Yamauchi, PS, Lask, GP, Patnaik, R, Iyer, S (2002). Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg, 28, 822–7.Google ScholarPubMed
Lowe, NJ, Glaser, DA, Eadie, N et al. (2007). North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol, 56, 604–11.CrossRefGoogle ScholarPubMed
Naumann, MK, Lowe, NJ for the Botox Hyperhidrosis Clinical Study Group (2001). Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ, 323, 1–4.CrossRefGoogle ScholarPubMed
Naumann, MK, Hamm, H, Lowe, NJ for the Botox Hyperhidrosis Clinical Study Group (2002). Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol, 147, 1218–26.CrossRefGoogle ScholarPubMed
Naumann, MK, Lowe, NJ, Kumar, CR, Hamm, H (2003). Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol, 139, 731–6.CrossRefGoogle ScholarPubMed
Saadia, D, Voustianiouk, A, Wang, AK, Kaufmann, H (2001). Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology, 57, 2095–9.CrossRefGoogle ScholarPubMed
Simonetta Moreau, M, Cauhepe, C, Magues, JP, Senard, JM (2003). A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol, 149, 1041–5.CrossRefGoogle ScholarPubMed
Strutton, DR, Kowalski, JW, Glaser, DA, Stang, PE (2004). US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol, 51, 241–8.CrossRefGoogle ScholarPubMed
Trindade de Almeida, AR, Secco, LC, Carruthers, A (2011). Handling botulinum toxins: an updated literature review. Dermatol Surg, 37, 1553–65.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×